Sign In
Buy GMDA
$0.0327
+0 (+0%)
At Close: Aug 27, 2024
Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel
07:00am, Tuesday, 28'th Oct 2025
LONDON--(BUSINESS WIRE)--Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to turn cells into powerful therapeutics, announced pos
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
04:04pm, Friday, 21'st Jun 2024
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical co
Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management
08:00am, Tuesday, 18'th Jun 2024
BOSTON--(BUSINESS WIRE)--Gamida Cell (the “Company”), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new executive leadership following a successful restr
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
11:16am, Wednesday, 27'th Mar 2024
Gamida Cell (NASDAQ: GMDA ) stock is falling hard on Wednesday after the clinical-stage biopharmaceutical company announced major changes to its business in its Q4 earnings report. This big news here
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript
11:01am, Wednesday, 27'th Mar 2024
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
07:00am, Wednesday, 27'th Mar 2024
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv)
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
07:00am, Wednesday, 27'th Mar 2024
Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 20
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
08:00am, Friday, 22'nd Mar 2024
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its f
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
08:00am, Friday, 23'rd Feb 2024
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubice
Gamida Cell Actively Pursuing Strategic Alternatives
06:00am, Monday, 29'th Jan 2024
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic al
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
08:00am, Wednesday, 17'th Jan 2024
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
08:11pm, Monday, 27'th Nov 2023
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought lead
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
08:00am, Monday, 20'th Nov 2023
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will presen
Gamida Cell Ltd. (GMDA) Q3 2023 Earnings Call Transcript
10:33am, Tuesday, 14'th Nov 2023
Gamida Cell Ltd. (NASDAQ:GMDA ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President & Chief Executiv
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
07:00am, Tuesday, 14'th Nov 2023
Company continues to advance launch, reports initial revenue from Omisirge ® (omidubicel-onlv)
